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Abstract
Canada’s Generation X is now entering the menopausal transition and pursuing effective therapy for bothersome
vasomotor symptoms. They do so at a time when confusion about the safe and appropriate use of menopausal
hormone therapy (MHT) has never been greater. Misplaced fears among women and their health care providers
about MHT have, in many circumstances, led them to abandon this most effective therapy. This review discusses
the physiology of the menopausal transition, the nature of symptoms related to withdrawal of ovarian estrogen
production, and the potential benefits and risks of MHT. It is now clear that for most recently menopausal women
the benefits of MHT outweigh the risks. The rationale for choosing different dosages, formulations, and regimens is
reviewed.
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Introduction
Those involved in the care of menopausal women when
the first Women’s Health Initiative (WHI) results were
published in 2002 will remember that year as pivotal in
the management of women entering the menopausal
transition. The sensational way that negative results were
fed to the media [1] triggered a cascade of events that
created a fear of menopausal hormone therapy (MHT)
leading women and their care providers to abandon the
most effective treatment for menopausal vasomotor
symptoms and substitute a variety of untested alterna-
tives for which the risk-benefit profile was largely
unknown.
In Canada for example, a reciprocal relationship in
prescribing practices for prescriptions of MHT and se-
lective serotonin reuptake inhibitors (SSRIs) was seen,
beginning in 2002. As shown in Fig. 1, the number of
prescriptions written for antidepressants increased while
those written for MHT quickly dropped off, suggesting
that “antidepressants were being prescribed for symp-
toms (psychological, physical) previously controlled with
the use of hormone replacement therapy” [2].
The absence of effective therapies for distressing vaso-
motor symptoms has contributed to a burgeoning market
for complementary and alternative medicines (CAMs) and
the unscrupulous marketing of purportedly “safer” hor-
mone therapy in the form of individualized compounded
bio-identical hormones [3]. There is, in fact, considerable
evidence that many CAMs are adulterated and fail to con-
tain the constituents as advertised. More so, most CAMs
have yet to establish any scientific evidence of efficacy be-
yond a placebo effect [4]. Ultimately, there is no evidence
that compounded bio-identical hormones are more effect-
ive or safer than regulated pharmaceuticals that have
undergone rigorous clinical trials before reaching the
market [5].
A significant shortcoming of the WHI was the inclu-
sion of women well beyond the age of menopause.
Women up to age 79 were eligible to participate and
ultimately, 2/3rds of recruited subjects were over age
60 years. A 2002 editorial warned of this flaw, suggesting
that if the role of exercise for cardiovascular disease pre-
vention had been tested in the same age group as the
WHI, it is likely that the number of induced cardiac
events would have led to the conclusion that exercise is
bad for the heart [6]. A full decade after the original
WHI report, a publication from several WHI lead inves-
tigators acknowledged that “the unfortunate effects of
the WHI came not from problems with the design or
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the findings; rather, they were the result of generalizing
findings from a well-conducted study to a subgroup that
was not adequately represented”. In other words, the
adverse consequences of MHT observed in older women
were, in error, extrapolated to younger, newly menopausal
women started on MHT. These authors further concluded:
“With initiation of HT near menopause, the weight of
evidence supports benefits over risks, with the potential to
prevent or ameliorate downstream morbidity” [7].
Unfortunately, the damage from 10 years of adverse
publicity about MHT has already been done. According
to Vincent Convello from the Centre for Risk Communi-
cation at Columbia University “strong beliefs about risk,
once formed, change very slowly and are extraordinarily
persistent in the face of contrary evidence”. This seems
particularly so for MHT. Despite the recent reanalyses
of the WHI, which confirm that benefits outweigh risks
for most newly menopausal women, fear and confusion
continue to linger. This is no doubt exacerbated by the
fact that rare adverse events remain a focus for media
and for lawyers looking to add additional treatments to
the 1–800 BAD-DRUG list.
Leading medical societies devoted to the care of meno-
pausal women in 2012 published a consensus document
to try to bring clarity to the benefits and risks of MHT
and concluded that “there is no question that hormone
therapy has an important role in managing symptoms
for women during the menopausal transition and in
early menopause” [8].
This reassurance however, is not enough because a gener-
ation of medical graduates have now been trained in an
environment where use of MHT is frowned upon. This has
resulted in limited or, in some cases, non-existent exposure
to prescribing MHT or addressing side effects of treatment.
This review will summarize benefits and risks of MHT
based on the best available evidence today and will
provide practitioners with directions to assist them in
prescribing MHT appropriately to women with disrup-
tive symptoms during the midlife transition.
Review
Understanding the menopausal transition
The developing follicle is the primary source of estrogen
in women during the reproductive years. In general, un-
less perturbed by pregnancy, extremes of body weight or
other hormonal disorders, the menstrual cycle through-
out the reproductive years tends to have a monthly peri-
odicity. As the pool of oocytes diminishes, women in
their 40’s often experience a decade of increasingly vari-
able menstrual cycle length.
Between the ages of 40 and 45, the process of oocyte
maturation accelerates, such that the follicular phase
shortens to 7–8 days instead of the typical 14 days in
younger women. An aberrant luteal phase elevation of
estrogen (a so-called LOOP event [9]) leads to an early
LH surge in the subsequent cycle and is considered one
explanation for this abbreviated follicular phase. In other
women, if the LOOP event does not result in ovulation,
it may lead to delayed follicular development and pro-
longation of the subsequent cycle. Coupled with heavier
and longer menses (often 8–10 days due to anatomic
(adenomyosis or fibroids) or other factors (excessive
prostacyclin or fibrinolytic activity), this menstrual cycle
irregularity will result in many women seeking treatment
for dysfunctional uterine bleeding.
Between the ages of 45 and 50, the remaining oocytes
are those that have been most resistant to gonadotropin
stimulation. Follicular development may halt temporarily
Fig. 1 Prescriptions of MHT and Selective serotonin reuptake inhibitors in Canada showing a reciprocal trend after 2002. With permission from
McIntyre RS, Konarski JZ, Grigoriadis S, Fan NC, Mancini DA, Fulton KA, Stewart DE, Kennedy SE. Hormone replacement therapy and
antidepressant prescription patterns: a reciprocal relationship CMAJ 2005; 172 (1):57–59. Reproduced with permission of the Canadian Medical
Association Journal
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until FSH levels rise sufficiently to force maturation.
During intervals with arrested follicular development,
estrogen levels fall and women experience the typical
menopausal hot flashes and night sweats. Then, if and
when follicular maturation resumes, estrogen levels rise
and menopausal symptoms subside, only to be replaced
by typical menstrual-cycle related symptoms such as
breast tenderness, bloating and mood changes followed
by often heavy and unpredictable menstruation.
The conventional term “perimenopause”, which was
originally defined by the World Health Organization, en-
compasses the period of time from the onset of men-
strual irregularity (usually in the mid 40’s) until one year
after the final menstrual period when the postmeno-
pausal phase begins [10]. More recently, the Stages of
Reproductive Aging Workshop + 10 (STRAW +10), de-
veloped an updated staging system for ovarian aging in
an attempt to standardize nomenclature. As such, the
period of time from onset of menstrual irregularity to
the final menstrual period is now defined as the “meno-
pausal transition” [11].
It is hardly surprising that the perimenopause is a time
of confusion and therapeutic frustration for women and
their health care providers alike. The intermittent nature
of clinical signs and symptoms of menopause leave un-
certainty about whether the final menstrual period has
occurred and with this variability, there may be confusion
about the ongoing need for contraception, menstrual cycle
regulation and/or hormone supplementation. Ultimately,
most women can expect to exhaust their pool of oocytes
by their mid-fifties with the average age of menopause be-
ing 51.5 years. Sustained amenorrhea with repeated eleva-
tion of FSH levels is diagnostic of menopause however
therapy for distressing symptoms need not be delayed
until the retrospective diagnosis of menopause has been
proven.
Typical early menopausal symptoms include hot
flashes and night sweats (vasomotor symptoms), and fre-
quent night time wakenings with subsequent daytime fa-
tigue or irritability [12]. Somatic aches and pains are the
most frequent symptoms reported by women entering
menopause [13, 14] but because most women assume
that arthritic changes are a natural part of aging, vaso-
motor symptoms remain the most common reason for
women to seek medical attention. In some women,
mood changes may play a major role and clinical depres-
sion is a documented consequence in susceptible indi-
viduals [15]. Later on, prolonged estrogen deficiency
plays a contributory role in the development of Genito-
urinary Syndrome of Menopause (GSM) – a condition
marked by the gradual development of vaginal dryness
and dyspareunia [16], increased risk for recurrent blad-
der or vaginal infections [17], and in some women, blad-
der overactivity.
Other effects of estrogen loss that lead to late clinical
manifestations include accelerated bone loss (contributing
to osteoporotic fractures) and certain adverse changes in
cardiovascular risk factors such as lipids, obesity, diabetes,
coronary artery calcium (CAC) accumulation and carotid
intima-media thickness – all contributors to cardiovascu-
lar diseases [18]. Premature loss of endogenous estrogen
has been shown to lead to earlier development of these
menopause-associated conditions [19, 20].
Benefits of MHT
Although estrogen therapy has been shown to diminish
somatic aches and pains and to reduce new onset of
joint symptoms in menopausal women [21, 22] this
seems to have remained a well-guarded secret. MHT
(estrogen alone, progestin alone, or combination ther-
apy) is best known for the dramatic relief afforded from
distressing vasomotor symptoms. Systemic estrogen sup-
plementation, even in low doses, can achieve up to an
80 percent decrease in hot flashes and night sweats with
the peak effect generally evident by 4 weeks of treatment
[23, 24].
Vaginal estrogen dosages recommended for treatment
of GSM result in minimal systemic absorption and are
therefore not effective for systemic complaints such as
joint pain or vasomotor symptoms. Higher doses of vagi-
nal estrogen do achieve systemic levels sufficient to con-
trol vasomotor symptoms [25].
The use of MHT confers the additional benefit of pro-
tecting against the accelerated bone loss of menopause
and should be considered first line treatment for bone
protection in symptomatic women [26]. The benefits of
estrogen for prevention of further bone loss and
stabilization of bone mineral density are seen even when
estrogen treatment is delayed for a number of years after
menopause [27] but the accelerated bone loss of meno-
pause resumes rapidly once estrogen is discontinued [28].
Systemic MHT sometimes, and vaginal estrogen ther-
apy almost always, provide protection of urogenital tis-
sues from the effects of diminished estrogen exposure
after menopause. Vaginal epithelium maintains healthy
rugation with a more normal stratified squamous cell
layer, better blood flow, and improved secretion (transu-
date), all of which contribute to better lubrication, less
dyspareunia, increased sensation, and greater sexual sat-
isfaction. Intravaginal but not systemic estrogen appears
to improve the symptom of urgency incontinence but re-
mains only one component of a multifaceted approach
to treatment of this condition [29].
The role of hormone therapy for prevention of coron-
ary artery disease (CAD) has been the focus of consider-
able confusion and debate [30, 31]. Observational
studies like the Nurse Health Study, which found that
MHT users were half as likely to develop CAD, are
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prone to certain biases due to differences in patient
characteristics and behaviours between the two groups.
MHT users differed in other attributes from non-MHT
users, in that they were more likely to adopt other health
promotion strategies like regular exercise and a healthy
diet [32]. The Women’s Health Initiative found that the
use of MHT soon after menopause did delay the onset
of coronary artery calcium (CAC) deposition [31, 33, 34]
and that women with VMS had less CAC, which was
attributed to prior MHT exposure [35]. In newly meno-
pausal women MHT resulted in a small reduction in
deaths due to CAD (1 fewer death per 1000 women
years). However, MHT started in older women or those
with pre-existing CAD increased the risk of adverse
events [36–38]. This and observations from animal stud-
ies suggesting that healthy coronary arteries respond dif-
ferently to estrogen than diseased vessels [39, 40] led to
the “window of opportunity” theory for initiation of
MHT while coronary arteries were still healthy [41].
We will probably never have the type of data needed to
completely resolve this issue. It would be extremely
difficult to recruit symptomatic newly menopausal women
to a placebo controlled trial of sufficient duration to see
outcome data for CAD. Depypere has calculated that it
would be necessary to enrol over 185,000 women to detect
a 10 % decrease in 10-year mortality [42].
MHT does appear to improve insulin sensitivity and
reduce the incidence of new onset diabetes mellitus [43].
The WHI found 1 fewer case of new onset diabetes per
625 women years of use [44]. Recent evidence indicates
that MHT has little impact on centripetal obesity, weight
gain or blood pressure [45–47].
Risks of MHT
Keeping perspective
As discussed above, the true risks of MHT have been in-
flated in the media, creating fear among many women
and health care providers [48]. The persistence of this
fear stems from a distorted perception of the apparent
risks, and this distortion that has been demonstrated by
a large Australian population survey [49]. Breast cancer
was perceived as a major health risk by 27 % of women
compared to only 11 % who cited heart disease as a con-
cern. In contrast to perceived risk, actual female mortal-
ity figures show that these conditions account for 3 %
and 41 % of mortality respectively.
What are the risks of MHT in the perimenopausal
or recently menopausal woman?
Cardiovascular diseases
Venous Thromboembolism (VTE)
Venous thromboembolism includes deep vein thrombosis
and pulmonary embolism. Advancing age and obesity are
important contributors to VTE risk in women on MHT
[50].
In the Women’s Health Initiative, women using MHT
between the ages of 50–59 experienced 1 more case of
VTE for every 1000 women per year [51]. This doubled
for women 60–69 and tripled for women 70–79.
Women with a body mass index (BMI) 25–30 kg/m2
had double the risk of women with BMI <25 kg/m2 and
in those with BMI >30 kg/m2 the risk was tripled.
Cigarette smoking does not appear to be a risk for VTE
though it is clearly a risk factor for coronary artery
disease and stroke [52].
Risk of VTE is greatest in the first year after initiation
of MHT, just as is seen with combined hormonal contra-
ception. Hence, the actual risk to women who have
safely used MHT for several years is probably lower than
short-term studies indicate.
Air travel has also been identified as an important
contributor to VTE, likely due to cramped seating, im-
mobility, hypoxia and dehydration. Recent research indi-
cates that risk of symptomatic events is 1/600 for flights
over 4 h and 1/500 for flights over 12 h in travellers over
50 years of age and that this risk may be doubled in
women on MHT [53].
Observational data suggest that the risk of VTE can be
reduced by using lower dose MHT or transdermal for-
mulations [54]. Findings from the large prospective
Million Women cohort study in the UK suggest that
estrogen-only MHT or combined estrogen/progestin
therapy (EPT) containing norgestrel/norethisterone pro-
gestins instead of medroxprogesterone actetate are also
associated with lower VTE risk [55].
Stroke
Stroke remains a leading cause of morbidity and mortal-
ity in women, so any effect of MHT on stroke risk could
be important. Results of past studies have been contra-
dictory with some showing protection from ischemic
stroke and others demonstrating small increases in risk.
In the WHI study, hemorrhagic stroke risk was not in-
fluenced by MHT.
The attributable risk for ischemic stroke in the com-
bined estrogen/progestin trial for all age groups was 0.9/
1000 women years. For women ages 50–59 years the
attributable risk of stroke was approximately 1/2500
women years of hormonal exposure [44, 56]. The attrib-
utable risk for all women enrolled in the estrogen alone
arm of the trial was 1.1/1000 women years. Women
aged 50–59 receiving estrogen alone showed no increase
in the risk of stroke compared to placebo users [44, 57].
The impact of MHT on ischemic stroke seems to be
related to hormone dosage and possibly also the route of
delivery [58]. Although transdermal delivery has been
suggested as a safer delivery route for MHT there is
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evidence that higher doses delivered transdermally may
still increase the risk of stroke [59].
Coronary Artery Disease (CAD)
As per the discussion above, MHT may carry a small
risk of a coronary event when started in women beyond
age 60 or more than 10 years after menopause because
coronary arteries may already be diseased by this time.
The absolute increase in mortality in older MHT users
in the WHI was small, at 1.6 per 1000 women years.
Nevertheless it is clear that co-morbidities (diabetes,
obesity, hypertension dyslipidemia, smoking, inactivity)
should be addressed before initiating MHT in older
women. The low absolute risk of adverse outcomes
should not preclude a clinical trial of MHT for distres-
sing VMS in women beyond age 60 or more than
10 years after menopause.
Cancers
Endometrial cancer
Unopposed estrogen in women with a uterus may lead to
endometrial neoplasia and in some cases this may become
apparent years after MHT treatment has been stopped.
The risk of progression from endometrial hyperplasia to
cancer depends on the type of hyperplasia identified.
When atypical features exist the risk of progression to
adenocarcinoma may be as high as 30 % [60].
Progestin co-therapy of sufficient dosage and duration
will generally protect against the risk of endometrial
neoplasia associated with unopposed estrogens [61]. For
many women, progestin co-therapy results in unwanted
side effects (spotting, mood changes and bloating) so
alternative approaches have been explored including
systemic estrogen combined with a progestin releasing
intrauterine system [62] or a combination of estrogen
and a selective estrogen receptor modulator [63].
Breast cancer
Breast cancer remains the greatest fear of most women
considering MHT. Much of the breast cancer anxiety
can be attributed to the enormous success of breast can-
cer awareness campaigns and the accompanying “pink
ribbon” merchandising of everything from Kentucky
Fried Chicken and Campbell’s soup to jewelry and per-
fume [64]. The challenge for health care providers is to
dispel distorted concepts about risk and to put true “ab-
solute” or “attributable” risks into perspective [65, 66].
Table1 shows the actual risks of breast cancer for a
hypothetical cohort of 1000 women over successive 10-
year intervals compared to other (mostly cardiovascular)
causes of mortality [67].
The WHI reported a hazard ratio for breast cancer
among women using combined estrogen/progestin ther-
apy of 1.3 with an attributable risk of 8/10,000 users per
year [68, 69]. In women randomized to estrogen-alone
the hazard ratio for breast cancer was 0.77 indicating an
attributable benefit of 7/10,000 fewer invasive breast
cancers per year [70, 71]. While other data on the effects
of estrogen on breast cancer are contradictory [72–74],
the weight of evidence suggests that the breast cancer
risk is lower with estrogen alone than with combined
estrogen/progestin therapy and that cancers may not
appear without longer term use [75].
The level of risk attributable to use of combined EPT
for more than 5 years is equivalent to the risk associated
with other biological determinants (early menarche, late
menopause, first birth after age 30, failure to breast feed,
postmenopausal obesity) or lifestyle choices (regular use
of alcohol, failure to exercise etc.) [76, 77].
Based on the level of risk “attributable “ to MHT
Collins has concluded that “When menopausal women
present with distressing vasomotor symptoms, they can
be reassured that short term (less than 5 years) use of
either combined EPT or E alone will have little appre-
ciable effect on their personal breast cancer risk. Longer
term use increases risk to a level similar to risks that
many women accept through lifestyles that expose them
to daily alcohol ingestion, lack of regular exercise and
postmenopausal obesity” [66].
For women who need MHT for control of distressing
VMS and those at high risk for osteoporosis where other
therapies may be poorly tolerated continued use beyond
5 years is appropriate after an individualized discussion
of benefits and risks [78].
Colorectal cancer
Several studies have demonstrated a reduction in colorec-
tal cancer incidence [79, 80] and mortality [81] in current
users, but not former users of MHT. In the WHI, al-
though the incidence of newly diagnosed colorectal can-
cers was lower in women on combined estrogen and
progestin therapy, there was no survival difference due to
more advanced stages of cancer in MHT users [82]. The
weight of evidence does not support the use of MHT for
colorectal cancer prevention.
Ovarian cancer
Several past studies have demonstrated a slight increase
in the incidence of serous and endometrioid ovarian
cancers and a decrease in mucinous ovarian cancers
among women using hormone therapy [83, 84]. This risk
disappeared within 2 years of cessation of MHT. The
attributable risk was very small with an extra ovarian
cancer occurring in 1/8,300 hormone users per year.
The WHI did not find an increase in ovarian cancer in-
cidence or mortality among MHT users [85].
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Lung cancer
Reassuring data indicating that MHT has no effect on
the incidence of lung cancer has come from several
long-term observational studies [86]. A pooled analysis
of 6 case control series involving close to 2000 lung can-
cer patients and a similar number of controls reported
by the International Lung Cancer Consortium even sug-
gested that MHT might reduce the risk of lung cancer
by 25-30 % [87]. Nevertheless, combined estrogen/pro-
gestin therapy has been suggested as a modifying factor
in the progression of lung cancer [88]. In the WHI, al-
though MHT did not significantly alter the incidence of
lung cancer, mortality from lung cancer was increased in
women using combined estrogen/progestin therapy [85].
Gall bladder disease
Published data have consistently shown that gallbladder
disease (gallstones and cholecystectomy rates) are in-
creased in current and former users of MHT (estrogen
alone more than combined estrogen/ progestin, and, oral
MHT more than transdermal MHT) [89, 90]. In the
WHI, there was one additional case of gallbladder dis-
ease per 200 women years of MHT use [44]. Estimates
suggest that transdermal MHT would avoid 1 cholecyst-
ectomy for every 600 women years of use [91].
Addressing the needs of the perimenopausal and
menopausal woman
The symptomatic perimenopausal woman
Therapy for intermittent menopausal symptoms (hot
flashes and night sweats) of the perimenopause need not
be delayed until menopause is confirmed. Rather it is
appropriate to begin treatment as soon as distressing
symptoms appear. Standard MHT may offer a dosage
that is too low to override the intermittent ovarian activ-
ity that characterizes the perimenopause. In this case a
low dose combined hormonal contraceptive may be ideal
for low risk non-smokers since it provides menstrual
cycle regulation, suppression of vasomotor symptoms,
and contraception. For smokers or individuals at higher
risk for cardiovascular complications (obesity, immobil-
ity or diabetes) an alternative would be to combine a
progestin releasing intrauterine system with systemic
transdermal estrogen. The device will suppress bleeding
and afford contraception while the transdermal estrogen
alleviates vasomotor symptoms.
The symptomatic menopausal woman
For women who present after menopause is clearly
established it is first important to elucidate the nature
and severity of symptoms, risk factors for CVD, osteo-
porosis and cancer, and the extent of any co-morbidities.
Ideally co-morbidities like diabetes, hypertension or dys-
lipidemia should be addressed before MHT is com-
menced. Before MHT is started a physical examination
is generally wise to evaluate for hypertension or any pre-
existing breast or pelvic abnormalities. An endometrial
biopsy or ultrasound to assess the endometrium should
be considered if any abnormal uterine bleeding has oc-
curred in the preceding months.
After a review of anticipated benefits and possible risks,
a joint decision between patient and practitioner should
be reached about the initial dosage, route of delivery, type
of estrogen and progestin and regimen. Estrogen, either
by itself or with progestins, is the most consistently effect-
ive therapy for hot flashes and night sweats.
Low-dose estrogen (doses of 0.3 mg of conjugated
equine estrogen, 0.5 mg of oral micronized estradiol, 25
ug of transdermal estradiol, or 2.5 mg of ethinyl estra-
diol) has been shown to be effective for many women,
although some women require a higher dose for relief of
hot flashes [92, 93]. No convincing clinical evidence sug-
gests that one product is safer or more efficacious than
the other. Initial relief from hot flashes is generally rapid
(within 1 week) but may take longer when treatment is
initiated with these very low doses [24].
In the absence of specific risk factors, route of delivery
can often be decided by the woman who will know best
how she can maintain therapy. Observational studies
suggest that transdermal delivery may be associated with
a reduced risk of VTE and possibly stroke [94]. There-
fore when specific risk factors for these conditions exist
(smoking, obesity, immobility, or a known personal/fam-
ily history of thrombophilia) a transdermal approach
should be recommended.
Which progestin to use in women with a uterus has
been the subject of considerable debate. Medroxyproges-
terone acetate (MPA) has been widely employed in MHT
throughout North America for several decades. It was
chosen for the WHI investigation because of its popularity
and widespread use at the time. Since then questions have
surfaced about the relative safety of different progestins
with some arguing for a switch to natural progesterone
Table 1 Chances of the development of, and death from,
breast cancer within the next 10 years for a cohort of 1000
women. With permission from Fletcher SW, Elmore JG. Clinical
practice: Mammographic screening for breast cancer. NEJM










40 yrs 15 2 21
50 yrs 28 5 55
60 yrs 37 7 126
70 yrs 43 9 309
80 yrs 35 11 670
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[92] and others arguing that experimental data on MPA
have not translated to clinical outcomes and that contin-
ued short term use of MPA is safe [95]. Used cyclically the
progestin dosage is MPA 5 mg or progesterone 200 mg for
10–12 days per month. With very low doses of estrogen,
especially if progestin causes side effects, progestin treat-
ment may be administered less frequently (every two or
three months). For continuous combined therapy the usual
progestin dosage is MPA is 2.5 mg or progesterone is
100 mg daily. Other specific combined formulations offer a
fixed dose of estrogen and progestin in a single tablet.
Traditionally, MHT employed a regimen that allowed
a one week hormone-free interval per month during
which time a small amount of scheduled bleeding might
occur. At these very low doses there is often minimal
endometrial growth and little, if any, withdrawal bleed-
ing. On the other hand, the hormone free week is often
punctuated by return of distressing vasomotor symp-
toms. This has led to a variety of continuous regimens
employing a daily combination of estrogen and progestin
in women with a uterus or estrogen alone for women
after hysterectomy. Personal tolerance to spotting or
preferences for scheduled cyclic bleeding may help de-
termine whether a continuous combined MHT regimen
would be preferred to a cyclic regimen with monthly
withdrawal bleeding.
Counselling should include what initial side effects to
anticipate (breast tenderness, spotting, discharge etc.)
and when a follow-up evaluation is warranted (unsched-
uled bleeding after 6 months). Generally, since the peak
benefit for vasomotor symptoms occurs at 1 month after
initiation, a follow-up appointment in two months works
well for a review. Remember to enquire about whether
the systemic therapy is adequately correcting any vaginal
dryness and dyspareunia – if not, add a prescription for
vaginal estrogen. If symptom control is good, and the
woman is satisfied, a one-year prescription and annual
review is appropriate.
Regular monitoring of bone mineral density is not re-
quired while on MHTas long as there are no other signifi-
cant risk factors for osteoporosis [19]. MHT may be
continued for as long as the distressing symptoms persist
for which the treatment was started. A brief (eg. 2 week)
break from MHT will allow women to rapidly discern
whether continued treatment is necessary for relief of
symptoms. Among women who stopped MHT after the
publication of the WHI, 25 % resumed therapy, presum-
ably due to severity of symptoms [93, 96]. Periodic review
of the need for treatment and an individualized discussion
of benefits and risks is appropriate when the prescription
is renewed. Often women will realize when therapy is no
longer needed for control of vasomotor symptoms and
this would be an appropriate time to discontinue sys-
temic therapy. When systemic treatment is stopped it is
important for the health care provider to counsel about
the possible development of Genitourinary Syndrome
of Menopause and therapeutic options available to pre-
vent this. As well, in anticipation of accelerated bone
loss in the next few years, a baseline BMD with follow-
up in 1.5 - 2 years is appropriate.
Conclusions
The perimenopause and menopause are periods of life
that can disrupt the quality of life for many women, so
an understanding of the pathophysiology and the poten-
tial consequences of waning ovarian estrogen production
can inform accurate counselling and management. Most
women considering MHT at this time of life can be in-
formed that risks are few and that in fact, the benefits
extend well beyond the control of vasomotor symptoms
that precipitated the visit. Regular follow-up with atten-
tion to co-morbidities and periodic review of individual
benefits and risks will allow for optimal duration of
treatment.
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